Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Cells|November 26, 2025
NeoPAIR-T: Functional Mapping of Neoantigen-TCR Pairs Using a CRISPR-Engineered Jurkat Reporter SystemKoji Nagaoka, Yukari Kobayashi, Kazuhiro KakimiInternational Immunology|December 31, 2011
Efficient capture of Candida albicans and zymosan by SIGNR1 augments TLR2-dependent TNF-α productionKazuhiko Takahara, Sumika Tokieda, Koji Nagaoka, et al.Scientific Reports|April 30, 2026
Mathematical modeling of immune counter-regulation predicts efficacy of fractionated CD8+ T cell dosing strategiesHiroki Kasai, Koji Nagaoka, Artem Lysenko, et al.European Journal of Immunology|March 15, 2011
C-type lectin SIGNR1 enhances cellular oxidative burst response against C. albicans in cooperation with Dectin-1Kazuhiko Takahara, Sumika Tokieda, Koji Nagaoka, et al.Journal of Leukocyte Biology|August 21, 2010
Expression of C-type lectin, SIGNR3, on subsets of dendritic cells, macrophages, and monocytesKoji Nagaoka, Kazuhiko Takahara, Kento Minamino, et al.Cancers|November 13, 2021
Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1Changbo Sun, Koji Nagaoka, Yukari Kobayashi, et al.Oncoimmunology|February 6, 2018
Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockadeKoji Nagaoka, Akihiro Hosoi, Tamaki Iino, et al.Journal of the American Chemical Society|October 2, 2024
Nanoenabled IL-15 Superagonist via Conditionally Stabilized Protein-Protein Interactions Eradicates Solid Tumors by Precise ImmunomodulationPengwen Chen, Shangwei Li, Koji Nagaoka, et al.International Immunopharmacology|October 7, 2014
Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLsKenji Miki, Koji Nagaoka, Mitsunori Harada, et al.International Journal of Cancer|December 1, 2022
Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumorsChangbo Sun, Koji Nagaoka, Yukari Kobayashi, et al.Pageof 4